Balyasny Asset Management
ACAD icon

Balyasny Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Balyasny Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,276,200
Closed -$19.5M – 1617
2018
Q2 		$19.5M Buy
1,276,200
+551,700
+76% +$9.84M 0.09% 316
2018
Q1 		$16.3M Buy
+724,500
New +$20.1M 0.07% 381
2016
Q2 		– Sell
-10,000
Closed -$280K – 1131
2016
Q1 		$280K Buy
+10,000
New +$218K ﹤0.01% 1027

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management's ACAD Position: Q2 2026 in Review

Balyasny Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 24% in Q2 2026, buying an estimated $1.65M and bringing the position to 388,024 shares worth $9.82M. The position accounts for 0.01% of the portfolio, ranked #1063.

Balyasny Asset Management first reported a position in ACAD in Q4 2016 and has held it in 19 quarters since. The position peaked at $26.1M in Q3 2018. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Balyasny Asset Management held 388,024 shares of Acadia Pharmaceuticals worth $9.82M as of Q2 2026.
  • Balyasny Asset Management bought 75,042 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Acadia Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1063 holding.
  • Balyasny Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
  • Balyasny Asset Management's Acadia Pharmaceuticals position peaked at $26.1M in Q3 2018.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.